10-Q: Quantum Genesis AI Reports Soaring Losses, Going Concern Doubts

Quantum Genesis AI Corp. reported a significant net loss of $4.38 million for the six months ended January 31, 2026, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $4,379,525 for the six months ended January 31, 2026, a substantial increase from $89,329 in the prior year period.
• The significant loss was primarily driven by a $4,325,872 loss on the conversion of debt.
• Cash balance stood at a mere $59 as of January 31, 2026, down from $584 on July 31, 2025.
• Total current liabilities were $418,401 against total current assets of $59, resulting in a working capital deficit of $418,342.
• The company has no revenues for the reported periods.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to recurring losses, accumulated deficit, and negative operating cash flows.
• 2,010,000 shares of common stock were issued to settle $60,300 in notes payable and $15,728 in accrued interest.
• The company's name changed from Quantumzyme Corp. to Quantum Genesis AI Corp. effective February 11, 2026.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative due to the severe financial distress, substantial net losses, critical cash levels, explicit going concern warning, and ineffective internal controls, indicating a high risk of business failure.

Positives

• Operating expenses decreased to $40,578 for the six months ended January 31, 2026, from $85,468 in the prior year, primarily due to decreased professional fees.
• Net cash used in operating activities slightly decreased to $43,810 for the six months ended January 31, 2026, from $49,575 in the prior year.

Negatives

• Reported a net loss of $4,379,525 for the six months ended January 31, 2026, a significant increase from $89,329 in the prior year.
• Incurred a $4,325,872 loss on the conversion of debt during the six months ended January 31, 2026.
• Cash balance is critically low at $59 as of January 31, 2026.
• Accumulated deficit reached $10,016,092 as of January 31, 2026.
• Has a working capital deficit of $418,342.
• No revenues were generated for the three and six months ended January 31, 2026, or 2025.
• Management concluded that disclosure controls and procedures were not effective.
• A material weakness in internal control over financial reporting exists due to limited resources and lack of segregation of duties.
• The company has no firm agreements for future financing and its ability to continue as a going concern is in substantial doubt.
• Issued 2,010,000 common shares, leading to significant dilution, to settle a relatively small amount of debt ($76,028 total).

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, accumulated deficit, and negative cash flows from operations.
• Complete dependence on attracting and receiving funding from the sale of securities or outside sources like private investment or strategic partners.
• Inability to obtain sufficient funding will restrict growth, reduce business operations, and may require suspension of operations, leading to loss for common stock purchasers.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• Litigation is subject to inherent uncertainties, and adverse results could harm business, financial condition, or operating results.
• Material weakness in financial reporting due to insufficient dedicated resources and experienced personnel, lack of optimal segregation of duties, and absence of an audit committee or independent audit committee financial expert.

Future Outlook

Management expects operating expenses to increase in future years due to increased operating activity under its business model. The company is entirely dependent on attracting and receiving funding from either the sale of securities or outside sources such as private investment or a strategic partner to continue operations and growth. There is no assurance that needed funds will be available on acceptable terms or at all, and failure to raise funds will likely require curtailment of development plans and may lead to suspension of operations.

Management Comments

• "We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner."
• "We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all."
• "The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations."
• "Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock."
• "If we are unable to obtain necessary financing, we will likely be required to curtail our development plans."
• "Any additional equity financing may involve substantial dilution to our then existing stockholders."
• "Management believes that the financial statements and other information presented herewith are materially correct, despite ineffective disclosure controls and material weaknesses in internal control over financial reporting."

Industry Context

StockSavvy.ai notes that Quantum Genesis AI Corp.'s pivot from office equipment distribution to the 'Enzyme Catalyst biotransformation sector' and then to 'AI' suggests a struggle to find a viable business model. The lack of revenue in these new, capital-intensive sectors, coupled with severe financial distress, indicates a significant disconnect from the growth and investment trends typically seen in successful AI or biotech companies. The company's situation contrasts sharply with established players or even promising startups in these fields that demonstrate clear product-market fit and robust funding.

Comparison to Industry Standards

• The company's cash balance of $59 and zero revenue are significantly below industry standards for any publicly traded company, especially those attempting to operate in capital-intensive sectors like AI or biotechnology.
• A working capital deficit of $418,342 and an accumulated deficit exceeding $10 million indicate severe financial distress, far from the healthy liquidity and profitability metrics expected of even early-stage growth companies.
• The substantial loss on debt conversion and subsequent dilution of common stock for a relatively small amount of debt settlement is highly unfavorable compared to typical financing structures in the industry, suggesting a distressed financial position.
• The explicit "going concern" warning and ineffective internal controls are red flags that would typically deter institutional investors and are not aligned with best practices for corporate governance and financial stability seen in comparable public companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings.
• From time to time, the company may be involved in legal proceedings or subject to claims incident to the ordinary course of business, with uncertain outcomes.

Related Party Transactions

• As of January 31, 2026, and July 31, 2025, the amount due to related parties was $16,602 and $17,002, respectively.
• Amounts due to related parties are non-interest bearing and due on demand.

Stakeholder Impact

• Shareholders: Significant dilution has occurred (2,010,000 shares issued for debt settlement), and further equity financing will likely cause substantial additional dilution. The "going concern" warning indicates a high risk of total loss of investment.
• Creditors: Promissory notes are due on 10 days written notice, and the company's critical cash position and going concern doubt suggest high risk of default.
• Employees: The company's severe financial distress and potential suspension of operations pose a high risk to job security.
• Customers/Suppliers: The company's inability to secure funding and its precarious financial state could impact its ability to fulfill obligations or maintain relationships.

Next Steps

• Management intends to take practical, cost-effective steps to implement internal controls upon obtaining sufficient capital and operations.
• Remedial measures for internal controls include assessing duties of existing personnel, potentially hiring additional personnel, reviewing Board composition, and considering an audit committee and financial expert.
• The company needs to attract and receive funding from the sale of securities or outside sources to continue operations.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a critically low cash balance of $59, zero revenue, a substantial net loss of over $4.3 million, and an explicit 'going concern' warning. The significant dilution from debt conversion and ineffective internal controls further highlight fundamental operational and financial instability. Without a clear path to revenue or secured financing, the risk of business failure is exceptionally high, making the stock a strong sell.

Keywords

Quantum Genesis AI Corp, 10-Q, Quarterly Report, Net Loss, Going Concern, Debt Conversion, Dilution, Financial Reporting, Internal Controls, AI, Enzyme Catalyst, Biotechnology, Financial Health, SEC Filing